MMR vaccination for children after heart transplant
Official title: Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
Run by Children's Mercy Hospital Kansas City · NCT07195032 · Data updated 2026-11-12
We will give the MMR (measles, mumps, rubella) vaccine to children and teens who had a heart transplant to see if it's safe and helps them make protective antibodies.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 1 Year to 17 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Children's Mercy Hospital Kansas City Academic / other |
| Drugs / interventions | rituximab, eculizumab, daratumumab, basiliximab |
| Locations | 1 site (Kansas City, Missouri) |
| Status | Recruiting |
| Started | September 11, 2025 |
| Main results expected | September 11, 2027 |
| Study ends | September 11, 2027 |
| Registry record updated | September 24, 2026 |
| Trial ID | NCT07195032 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and adolescents (12 months–17 years) who had a heart transplant at least one year ago, meet the required time intervals since specific immunosuppressive or rejection treatments, are clinically well, and are either unvaccinated or measles-seronegative.
✕Probably not a fit
Patients with recent or ongoing intensive immunosuppression, a history of repeated infections requiring non-standard immunosuppression adjustments, or a prior anaphylactic reaction to MMR are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a non-randomized interventional study enrolling children and adolescents (12 months to 17 years) who have undergone heart transplantation. Eligible participants who are clinically well and meet timing criteria after transplant and prior immunomodulatory treatments will receive the licensed commercial MMR vaccine according to product labeling. The study will monitor safety outcomes and measure antibody responses to determine whether vaccination induces protective immunity without causing adverse events. Results aim to inform guidance on when live MMR vaccine can be given after pediatric heart transplantation.
Why it matters
Potential benefit: If successful, vaccination could safely restore measles, mumps, and rubella immunity and reduce the risk of these infections in pediatric heart transplant recipients.
How similar studies have gone: Small reports and studies in other pediatric solid-organ transplant populations suggest live vaccines can be safe and immunogenic in carefully selected patients, but data specifically in heart transplant recipients are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Received a heart transplant * At least 1 year after transplant * At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab) * At least 1 year from anti-thymocyte globulin * At least 6 months after pulse dose steroid treatment or basiliximab treatment * No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion * Clinically well Exclusion Criteria: * History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels. * History of anaphylactic reaction to MMR vaccination
Where it's running
-
Children's Mercy Hospital
Kansas City, Missouri, United States Recruiting
Study contacts
- Principal investigator: Victoria Blazek, PharmD, BCPPS — Children's Mercy Hospital Kansas City
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Regulating Together for Emotion Dysregulation in ASD and Intellectual Disability (group therapy)
This study tests a group therapy program for kids with autism and co-occurring intellectual disability to help them manage irritability and aggression, with sessions for both children and their caregivers.
-
Group therapy to help teens with Prader-Willi regulate emotions
Teens with Prader-Willi Syndrome and their families will try a group therapy program to help calm emotions and reduce irritability and anxiety.
-
Portable MRI for kids with hypoxic brain injury
This study tests whether a bedside, low-field portable MRI can accurately detect hypoxic-ischemic brain injuries in children compared with standard imaging.
-
Trying ViBandz for children with neurologic movement problems
We will try the ViBandz vibration device with children aged 6 months to 17 years who have neurologic movement problems during their regular PT/OT clinic visit.
-
Home-based VR neurofeedback for adolescents with migraine
This program tests whether a home-based virtual reality system guided by a wearable EEG headband can help adolescents (ages 10–16) who have migraine.
-
Bleeding patterns with sequential versus continuous progesterone in adolescents with Turner syndrome
This study will test whether taking progesterone continuously or in a sequential (monthly) schedule changes bleeding patterns in adolescents with Turner syndrome who are on estrogen replacement therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.